<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">9HZBnsvLSnZZvCrdZ94kytP</article-id>
      <article-id pub-id-type="other">00016</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000300016</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200316</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000300016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Choque cardiog&#234;nico por dissulfiram</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jer&#243;nimo</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meira</surname>
            <given-names>Carla</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amaro</surname>
            <given-names>Augusta</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campello</surname>
            <given-names>Gl&#243;ria Cabral</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Granja</surname>
            <given-names>Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Matosinhos</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Pedro Hispano</institution>
        <institution content-type="orgdiv1">Servi&#231;o de Cuidados Intensivos </institution>
        <country country="PT">Portugal</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>3</issue>
      <fpage>e43</fpage>
      <lpage>e45</lpage>
      <history>
        <date date-type="rev-recd">
          <day>28</day>
          <month>06</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>25</day>
          <month>03</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>09</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A intoxica&#231;&#227;o medicamentosa por dissulfiram &#233; uma situa&#231;&#227;o rara, mas, que pode se apresentar com manifesta&#231;&#245;es cardiovasculares graves e potencialmente fatais, como choque cardiog&#234;nico. &#201; apresentado o caso de uma paciente com choque refrat&#225;rio, ap&#243;s intoxica&#231;&#227;o volunt&#225;ria por dissulfiram. A avalia&#231;&#227;o cl&#237;nica e bioqu&#237;mica, junto &#224; avalia&#231;&#227;o ecocardiogr&#225;fica e &#224; monitoriza&#231;&#227;o invasiva, confirmaram tratar-se de um choque cardiog&#234;nico associado a esse f&#225;rmaco. S&#227;o discutidos os mecanismos de a&#231;&#227;o conhecidos do dissulfiram e descritos os principais efeitos colaterais, especialmente os cardiovasculares, alertando para a import&#226;ncia da suspei&#231;&#227;o diagn&#243;stica e da abordagem terap&#234;utica imediata mais adequada nesse contexto.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Choque cardiog&#234;nico</kwd>
        <kwd>dissulfiram</kwd>
        <kwd>efeitos adversos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>17</day>
        <month>04</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>
      <bold>Choque cardiog&#234;nico por dissulfiram</bold>
    </p>
    <p>
      <bold>Ana Jer&#243;nimo; Carla Meira; Augusta Amaro; Gl&#243;ria Cabral Campello; Cristina Granja</bold>
    </p>
    <p>Servi&#231;o de Cuidados Intensivos, Hospital Pedro Hispano, Matosinhos - Portugal</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>A intoxica&#231;&#227;o medicamentosa por dissulfiram &#233; uma situa&#231;&#227;o rara, mas, que pode se apresentar com manifesta&#231;&#245;es cardiovasculares graves e potencialmente fatais, como choque cardiog&#234;nico. &#201; apresentado o caso de uma paciente com choque refrat&#225;rio, ap&#243;s intoxica&#231;&#227;o volunt&#225;ria por dissulfiram. A avalia&#231;&#227;o cl&#237;nica e bioqu&#237;mica, junto &#224; avalia&#231;&#227;o ecocardiogr&#225;fica e &#224; monitoriza&#231;&#227;o invasiva, confirmaram tratar-se de um choque cardiog&#234;nico associado a esse f&#225;rmaco. S&#227;o discutidos os mecanismos de a&#231;&#227;o conhecidos do dissulfiram e descritos os principais efeitos colaterais, especialmente os cardiovasculares, alertando para a import&#226;ncia da suspei&#231;&#227;o diagn&#243;stica e da abordagem terap&#234;utica imediata mais adequada nesse contexto.</p>
    <p><bold>Palavras-chave: </bold>Choque cardiog&#234;nico, dissulfiram/envenenamento, efeitos adversos.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A intoxica&#231;&#227;o medicamentosa volunt&#225;ria &#233; um importante problema de sa&#250;de mundial, com um n&#250;mero substancial de pacientes a exigir admiss&#227;o em Unidades de Terapia Intensiva (UTI), por se apresentarem em coma ou com instabilidade hemodin&#226;mica. Antidepressivos, benzodiazepinas e organofosforados s&#227;o os f&#225;rmacos mais utilizados, muitas vezes, em associa&#231;&#227;o entre eles e com bebidas alco&#243;licas<sup>1</sup>. Intoxica&#231;&#245;es volunt&#225;rias por dissulfiram s&#227;o raras, mas a gravidade das complica&#231;&#245;es agudas exige que se saiba reconhecer os seus efeitos t&#243;xicos.</p>
    <p>O dissulfiram, usado para o tratamento do alcoolismo, exerce sua a&#231;&#227;o quando h&#225; ingest&#227;o concomitante de &#225;lcool. Ele inibe de forma irrevers&#237;vel a enzima alde&#237;do-desidrogenase respons&#225;vel pela metaboliza&#231;&#227;o do etanol, com aumento da concentra&#231;&#227;o s&#233;rica do metab&#243;lito acetalde&#237;do, cuja toxicidade provoca a "s&#237;ndrome do acetalde&#237;do". Trata-se de uma rea&#231;&#227;o t&#237;pica auto-limitada, com cefal&#233;ias, <italic>flushing</italic>, tonturas, n&#225;usea, vis&#227;o turva, tremor e dispn&#233;ia<sup>2</sup>. N&#227;o associado &#224; ingest&#227;o de &#225;lcool, seus efeitos s&#227;o escassos nas doses di&#225;rias habituais. J&#225; a intoxica&#231;&#227;o aguda em doses superiores a 500 mg/dia pode ter como consequ&#234;ncia efeitos colaterais graves, podendo ser letais entre 10 - 30 g/dia<sup>3</sup>.</p>
    <p>
      <bold>Relato de Caso</bold>
    </p>
    <p>Paciente do sexo feminino, <italic>49</italic> anos, com depress&#227;o maior e alcoolismo cr&#244;nico. Admitida no Pronto-Socorro quatro horas ap&#243;s ingest&#227;o volunt&#225;ria de 60 comprimidos de dissulf&#239;ram (15g), 16 comprimidos de clonazepam (8mg) e 6 comprimidos de maprotilina (450mg), associada ao consumo de &#225;lcool.</p>
    <p>Do exame cl&#237;nico, destacavam-se sonol&#234;ncia, taquipn&#233;ica e m&#225; perfus&#227;o perif&#233;rica. Press&#227;o arterial: 68 - 35 mmHg; frequ&#234;ncia card&#237;aca: 105 bpm. Ausculta pulmonar com estertores bolhosos difusos.</p>
    <p>Dos resultados bioqu&#237;micos, salientava-se uma prote&#237;na C reativa elevada (PCR) - 31 mg/dl. A gasometria revelava hipoxemia grave (PaO<sub>2</sub> 66 mmHg, com FiO<sub>2</sub> 85%).</p>
    <p>Os marcadores de isquemia mioc&#225;rdica eram negativos. O eletrocardiograma mostrava taquicardia sinusal, sem altera&#231;&#245;es compat&#237;veis com isquemia aguda. A radiografia de t&#243;rax apresentava opacidades alveolares bilaterais (<xref ref-type="fig" rid="f1">Fig 1</xref>).</p>
    <p content-type="asset">
      <fig id="f1">
        <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gf01.jpg"/></fig>
    </p>
    <p>Foram iniciadas de imediato medidas de ressuscita&#231;&#227;o de volume e posteriormente dopamina. Colheu-se rastreio microbiol&#243;gico e iniciou-se antibioterapia de largo espectro. Apesar dessas medidas, a paciente manteve choque refrat&#225;rio e evoluiu com agravamento da dificuldade respirat&#243;ria e dessatura&#231;&#227;o progressiva, exigindo intuba&#231;&#227;o orotraqueal e in&#237;cio de ventila&#231;&#227;o mec&#226;nica, tendo sido admitida na UTI.</p>
    <p>O quadro foi inicialmente interpretado como choque misto - cardiog&#234;nico e s&#233;ptico. A sepses era assumida como componente principal, com ponto de partida em poss&#237;vel pneumonia de aspira&#231;&#227;o devido &#224; prostra&#231;&#227;o. O componente cardiog&#234;nico seria resultante dos efeitos colaterais dos medicamentos ingeridos.</p>
    <p>Persistindo d&#250;vidas relativas ao grau de comprometimento card&#237;aco, foi realizado ecocardiograma que mostrou preju&#237;zo moderado da fun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo, com fra&#231;&#227;o de eje&#231;&#227;o de 36% e hipocin&#233;sia global, sem outras altera&#231;&#245;es. Esses resultados motivaram monitoriza&#231;&#227;o hemodin&#226;mica invasiva com cat&#233;ter de PICCO (<italic>Pulse Induced Continuous Cardiac Output</italic>), que confirmou perfil compat&#237;vel com choque cardiog&#234;nico puro, com &#237;ndice card&#237;aco baixo e resist&#234;ncias vasculares perif&#233;ricas elevadas (<xref ref-type="table" rid="t1">Tabela 1</xref>).</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gt01.jpg"/></table-wrap>
    <p>Nesse contexto, foi substitu&#237;da dopamina por dobutamina e suspendido antibi&#243;tico nas primeiras 24h. Verificou-se, posteriormente, redu&#231;&#227;o progressiva da PCR at&#233; normaliza&#231;&#227;o. Os marcadores card&#237;acos seriados e eletrocardiograma permaneceram normais e a paciente n&#227;o apresentou perturba&#231;&#245;es da condu&#231;&#227;o ou ritmo.</p>
    <p>As imagens radiol&#243;gicas foram reinterpretadas como edema pulmonar cardiog&#234;nico, em substitui&#231;&#227;o das hip&#243;teses iniciais de pneumonia. A corroborar essa hip&#243;tese, o fato de as altera&#231;&#245;es radiol&#243;gicas terem se resolvido, nas primeiras horas ap&#243;s o in&#237;cio da ventila&#231;&#227;o mec&#226;nica e do ajuste de aminas, com melhoria da fun&#231;&#227;o card&#237;aca global (<xref ref-type="fig" rid="f1">Fig 1</xref>).</p>
    <p>Verificou-se resolu&#231;&#227;o do choque circulat&#243;rio ao fim de 72 horas e melhoria dos par&#226;metros ventilat&#243;rios permitindo extuba&#231;&#227;o no 4&#186; dia. J&#225; sem suporte de aminas, repetiu-se ecocardiograma, tendo-se verificado uma melhoria na fun&#231;&#227;o sist&#243;lica (fra&#231;&#227;o de eje&#231;&#227;o de 52%) e regress&#227;o da hipocin&#233;sia global. A paciente manteve evolu&#231;&#227;o favor&#225;vel do ponto de vista cardiovascular, tendo tido alta da UTI acordada e colaborante, hemodinamicamente est&#225;vel e sem sinais de insufici&#234;ncia card&#237;aca.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Ap&#243;s exclu&#237;das outras hip&#243;teses, o quadro agudo de choque cardiog&#234;nico foi interpretado no contexto da intoxica&#231;&#227;o medicamentosa por dissulfiram. Com marcadores s&#233;ricos card&#237;acos e eletrocardiograma persistentemente normais, excluiu-se o diagn&#243;stico de infarto agudo do mioc&#225;rdio. N&#227;o havia altera&#231;&#245;es valvulares ou estruturais card&#237;acas compat&#237;veis com miocardiopatia dilatada.</p>
    <p>De fato, a evolu&#231;&#227;o para choque cardiog&#234;nico pode ser uma das complica&#231;&#245;es graves da intoxica&#231;&#227;o aguda por dissulfiram, por vezes dif&#237;cil de reconhecer na abordagem inicial do paciente. Al&#233;m de se tratar de uma complica&#231;&#227;o rara, os pacientes s&#227;o na sua maioria jovens, sem antecedentes de patologia card&#237;aca.</p>
    <p>A instabilidade hemodin&#226;mica pode facilmente ser interpretada em um contexto de sepse ou SDRA em vez de fal&#234;ncia circulat&#243;ria subsequente &#224; intoxica&#231;&#227;o medicamentosa, atrasando a avalia&#231;&#227;o da fun&#231;&#227;o card&#237;aca.</p>
    <p>As manifesta&#231;&#245;es da toxicidade aguda por dissulfiram resultam da potencia&#231;&#227;o da rea&#231;&#227;o do acetalde&#237;do, quando associada ao &#225;lcool, mas, sobretudo dos efeitos diretos do f&#225;rmaco. Podem complicar-se com depress&#227;o respirat&#243;ria, altera&#231;&#245;es neurol&#243;gicas, infarto agudo do mioc&#225;rdio, arritmias, depress&#227;o card&#237;aca ou choque cardiog&#234;nico, podendo mesmo levar &#224; morte<sup>3,4</sup>. Nos primeiros anos da sua utiliza&#231;&#227;o, o dissulfiram era prescrito em doses muito elevadas, em alguns casos, at&#233; 3 g/dia, o que resultou em uma taxa aumentada de rea&#231;&#245;es graves ou fatais<sup>5</sup>. As doses foram sendo ajustadas e rea&#231;&#245;es deste tipo j&#225; s&#227;o raras, atualmente observadas, quase em exclusivo, nos casos de ingest&#227;o volunt&#225;ria ou acidental, com doses claramente supra-terap&#234;uticas, ou em pacientes com patologia cardiovascular pr&#233;via. Atualmente, s&#227;o escassos os casos reportados de colapso cardiovascular, com um quadro semelhante ao descrito nesta paciente<sup>6,7</sup>.</p>
    <p>Dado n&#227;o existir ant&#237;doto espec&#237;fico, o tratamento agressivo de suporte tem constitu&#237;do a base terap&#234;utica. Ao longo dos anos, foram constatadas diferen&#231;as entre as aminas usadas como suporte hemodin&#226;mico, verificando-se que a noradrenalina &#233; mais eficaz que a dopamina.</p>
    <p>Pensa-se que isso se deva aos efeitos de um dos pr&#243;prios metab&#243;litos do dissulfiram, o dieltilditiocarbamato, que atenua o efeito da resposta adren&#233;rgica &#224; hipotens&#227;o atrav&#233;s da inibi&#231;&#227;o da dopamina-beta-hidroxilase, enzima que converte a dopamina em noradrenalina<sup>6,8</sup>. A deple&#231;&#227;o de noradrenalina no cora&#231;&#227;o e nos vasos permite a a&#231;&#227;o direta do acetalde&#237;do nesses tecidos, produzindo os sintomas t&#237;picos cardiovasculares, incluindo hipotens&#227;o grave. &#201; poss&#237;vel que esse seja tamb&#233;m o mecanismo que condiciona depress&#227;o mioc&#225;rdica global, levando posteriormente ao choque. Em fun&#231;&#227;o desses dados, a noradrenalina ou adrenalina parecem ser op&#231;&#245;es adequadas para o tratamento desses casos<sup>9</sup>.</p>
    <p>A efic&#225;cia da dobutamina nunca foi suficientemente avaliada. Na nossa paciente, a dobutamina mostrou ser uma alternativa eficaz.</p>
    <p>O contributo dos restantes f&#225;rmacos ingeridos para o desenvolvimento do quadro foi questionado. Ap&#243;s revis&#227;o de todos os seus efeitos colaterais, confirmou-se que a maprotilina (antidepressivo tetrac&#237;clico, semelhante aos tric&#237;clicos), ao contr&#225;rio do dissulfiram, n&#227;o apresenta potencial para provocar situa&#231;&#245;es de choque cardiog&#234;nico.</p>
    <p>Os principais efeitos colaterais dos antidepressivos tric&#237;clicos s&#227;o os dist&#250;rbios da condu&#231;&#227;o card&#237;aca (prolongamento do QRS e intervalo QT ou bloqueio aur&#237;culo-ventricular). Podem ainda provocar hipotens&#227;o postural (por bloqueio dos receptores alfa-1 adren&#233;rgicos), mas em grau ligeiro e que se reverte facilmente com fluidoterapia.</p>
    <p>A maprotilina &#233;, al&#233;m disso, menos cardiot&#243;xica que os demais antidepressivos do mesmo grupo. Mesmo em situa&#231;&#245;es de sobredosagem, n&#227;o est&#227;o descritos efeitos hemodin&#226;micos graves como choque cardiog&#234;nico, sobretudo em pacientes sem cardiopatia pr&#233;via<sup>10</sup>.</p>
    <p>Assim, considerou-se que a contribui&#231;&#227;o da maprotilina para o quadro de fal&#234;ncia circulat&#243;ria n&#227;o foi determinante e seu efeito, se presente, seria rapidamente corrigido pelas medidas terap&#234;uticas agressivas iniciais.</p>
    <p>O clonazepam (benzodiazepina) apresenta escassos efeitos cardiovasculares que incluem sobretudo palpita&#231;&#245;es, n&#227;o apresentando a&#231;&#227;o hipotensora nem depressora card&#237;aca<sup>4</sup>.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A intoxica&#231;&#227;o medicamentosa com dissulfiram pode ter manifesta&#231;&#245;es cardiovasculares graves, com choque cardiog&#234;nico refrat&#225;rio e depress&#227;o mioc&#225;rdica aguda. Esses pacientes devem manter uma vigil&#226;ncia cl&#237;nica apertada e obter uma avalia&#231;&#227;o precoce da fun&#231;&#227;o card&#237;aca. A monitoriza&#231;&#227;o hemodin&#226;mica invasiva e o suporte ventilat&#243;rio em ambiente de terapia intensiva podem ser necess&#225;rios. A dopamina parece ser a amina com menor efic&#225;cia na abordagem do choque provocado por este f&#225;rmaco.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p>Ana Jer&#243;nimo </p>
        <p> R. Prof. Ferreira Mendes, 44, Valbom </p>
        <p> 4420-537 - Gondomar - Portugal </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="anajeronimo@hotmail.com">anajeronimo@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 25/03/2008; revisado recebido 28/06/08; aceito em 23/09/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Novack V, Jotkowitz    A, Delgado J, Novack L, Elbaz G, Shleyfer E, et al. General characteristics    of hospitalized patients after deliberate self-poisoning and risk factors for    intensive care admission. Eur J Intern Med. 2006; 17 (7): 485-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>General characteristics of hospitalized patients after deliberate self-poisoning and risk factors for intensive care admission</article-title>
          <source>Eur J Intern Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>485</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Novack</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jotkowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Delgado</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Novack</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Elbaz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shleyfer</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Wright C, Moore    RD. Disulfiram treatment of alcoholism. Am J Med. 1990; 88: 647-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Disulfiram treatment of alcoholism</article-title>
          <source>Am J Med</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>647</fpage>
          <lpage>55</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Petersen EN.    The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr    Scand Suppl. 1992; 369: 7-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The pharmacology and toxicology of disulfiram and its metabolites</article-title>
          <source>Acta Psychiatr Scand Suppl</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <volume>369</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Petersen</surname>
              <given-names>EN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Brunton L, Lazo    J, Parker K. (eds). Goodman &amp; Gilman: the pharmacological basis of therapeutics.    11th ed. New York: McGraw-Hill; 2006.</mixed-citation>
        <element-citation publication-type="book">
          <source>Goodman &amp; Gilman: the pharmacological basis of therapeutics</source>
          <date>
            <year>2006</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Brunton</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lazo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Jacobsen E.    Deaths of alcoholic patients treated with disulfiram. Q J Stud Alcohol. 1952;    13: 16-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Deaths of alcoholic patients treated with disulfiram</article-title>
          <source>Q J Stud Alcohol</source>
          <date>
            <year>1952</year>
          </date>
          <fpage>16</fpage>
          <lpage>26</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsen</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Motte S, Vincent    JL, Gillet JB, Deguate JP, Kahn RJ. Refractory hyperdynamic shock associated    with alcohol and disulfiram. Am J Emerg Med. 1986; 4 (4): 323-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Refractory hyperdynamic shock associated with alcohol and disulfiram</article-title>
          <source>Am J Emerg Med</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>323</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Motte</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vincent</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Gillet</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Deguate</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Ho MP, Yo CH,    Liu CM, Chen CL, Lee C. Refractive hypotension in a patient with disulfiram-ethanol    reaction. Am J Med Sci. 2007; 333 (1): 53-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Refractive hypotension in a patient with disulfiram-ethanol reaction</article-title>
          <source>Am J Med Sci</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>53</fpage>
          <lpage>5</lpage>
          <issue>1</issue>
          <volume>333</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Yo</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Tottmar O, Hellstrom    E. Blood pressure response to ethanol in relation to acetaldehyde levels and    dopamine-beta-hydroxylase activity in rats pretreated with disulfiram, cyanamide    and coprine. Acta Pharmacol Toxicol. 1979; 45: 272-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Blood pressure response to ethanol in relation to acetaldehyde levels and dopamine-beta-hydroxylase activity in rats pretreated with disulfiram, cyanamide and coprine</article-title>
          <source>Acta Pharmacol Toxicol</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>272</fpage>
          <lpage>81</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tottmar</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hellstrom</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Moller LM, Pedersen    B. High-dose adrenaline in the treatment of severe hypotensive crisis caused    by disulfiram ethanol reaction. Ugeskr Laeger. 1990; 152: 2437-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High-dose adrenaline in the treatment of severe hypotensive crisis caused by disulfiram ethanol reaction</article-title>
          <source>Ugeskr Laeger</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>2437</fpage>
          <lpage>8</lpage>
          <volume>152</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moller</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Rays J, Wajngarten    M. Antidepressivos e doen&#231;as cardiovasculares. Rev Soc Cardiol Estado    de S&#227;o Paulo. 1998; 8 (6): 11-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Antidepressivos e doen&#231;as cardiovasculares</article-title>
          <source>Rev Soc Cardiol Estado de S&#227;o Paulo</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>11</fpage>
          <lpage>6</lpage>
          <issue>6</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rays</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wajngarten</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Cardiogenic shock caused by disulfiram</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Drug intoxication with disulfiram is a rare condition that may lead to severe and potentially fatal cardiovascular manifestations such as cardiogenic shock. We report the case of a female patient with refractory shock after deliberate self-poisoning with disulfiram. Clinical, biochemical and echocardiographic assessment, as well as invasive monitoring confirmed cardiogenic shock associated with this drug. The known mechanisms of action of disulfiram are discussed, and the major collateral effects, especially cardiovascular effects, are described. We underscore the importance of suspecting this diagnosis and of adopting prompt and the most adequate therapeutic approach in this context.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Shock, cardiogenic</kwd>
        <kwd>disulfiram</kwd>
        <kwd>adverse effects</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Cardiogenic shock caused by disulfiram</bold>
          </label>
          <p>
            <bold>Ana Jer&#243;nimo; Carla Meira; Augusta Amaro; Gl&#243;ria Cabral Campello; Cristina Granja</bold>
          </p>
        </fn>
      </p>
      <p>Servi&#231;o de Cuidados Intensivos, Hospital Pedro Hispano, Matosinhos - Portugal</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p>Drug intoxication with disulfiram is a rare condition that may lead to severe and potentially fatal cardiovascular manifestations such as cardiogenic shock. We report the case of a female patient with refractory shock after deliberate self-poisoning with disulfiram. Clinical, biochemical and echocardiographic assessment, as well as invasive monitoring confirmed cardiogenic shock associated with this drug. The known mechanisms of action of disulfiram are discussed, and the major collateral effects, especially cardiovascular effects, are described. We underscore the importance of suspecting this diagnosis and of adopting prompt and the most adequate therapeutic approach in this context.</p>
      <p><bold>Key Words:</bold>Shock, cardiogenic; disulfiram/poisoning, adverse effects.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Deliberate self-poisoning is an important health problem worldwide, with a substantial number of patients requiring admission in Intensive Care Units (ICU) due to coma or hemodynamic instability. Antidepressants, benzodiazepines and organosphosphates are the most frequently used drugs, commonly associated with each other or with alcoholic beverages<sup>1</sup>. Deliberate self-poisoning with disulfiram is uncommon, but the severity of the acute complications requires that its toxic effects be recognized.</p>
      <p>Disulfiram, which is used for the treatment of alcoholism, exerts its action when taken concomitantly with alcohol. It irreversibly inhibits the aldehyde dehydrogenase enzyme which is responsible for ethanol metabolization, thus leading to increased serum concentration of the metabolite acetaldehyde, whose toxicity results in the "acetaldehyde syndrome". The typical reaction is self-limited, with headache, flushing, dizziness, nausea, blurred vision, tremor and dyspnea<sup>2</sup>. When not associated with alcohol ingestion, its effects are scarce at usual daily doses. Acute intoxication at doses higher than 500 mg/day, in turn, may result in severe collateral effects, and can be lethal at doses between 10-30g/day<sup>3</sup>.</p>
      <p>
        <bold>Case Report</bold>
      </p>
      <p>A 49-year-old female patient with major depression and chronic alcoholism was admitted to the emergency room four hours after deliberate ingestion of 60 disulfiram tablets (15g), 16 clonazepam tablets (8mg) and six maprotiline tablets (450mg), in association with alcohol.</p>
      <p>Her clinical examination was notable for sleeplessness, tachypnea, and poor peripheral perfusion. Blood pressure: 68 x 35mmHg; heart rate: 105 bpm. Pulmonary auscultation revealed diffuse coarse crackles.</p>
      <p>Laboratory studies were significant for increased C-reactive protein (CRP) - 31 mg/dL. Her blood gas showed severe hypoxemia (PaO<sub>2</sub> 66 mmHg, with FiO<sub>2</sub> 85%).</p>
      <p>Markers of myocardial ischemia resulted negative. Electrocardiography showed sinus tachycardia, with no changes consistent with acute ischemia. Chest radiography showed alveolar opacities bilaterally (<xref ref-type="fig" rid="en_16f1-body2">Figure 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_16f1-body2">
          <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gf01-en.jpg"/></fig>
      </p>
      <p>Volume resuscitation measures were introduced immediately, followed by dopamine. Blood cultures were collected and broad-spectrum antibiotic therapy was started. Despite these measures, the patient remained in refractory shock and progressed with worsening of the respiratory distress and increasing desaturation. Orotracheal intubation was required and mechanical ventilation was started. The patient was transferred to the ICU.</p>
      <p>The clinical picture was initially interpreted as mixed - cardiogenic and septic - shock. Sepsis was assumed as the major component, having possibly originated from aspiration pneumonia due to prostration. The cardiogenic component could result from the collateral effects of the medications taken.</p>
      <p>In order to clarify the degree of cardiac involvement, an echocardiography was performed, showing moderate impairment of the left ventricular systolic function, with a 36% ejection fraction and global hypokinesia, with no other abnormalities. In light of these findings, invasive hemodynamic monitoring with a PICCO (Pulse Induced Continuous Cardiac Output) catheter was started, confirming a profile consistent with pure cardiogenic shock, with low cardiac index and high peripheral vascular resistances (<xref ref-type="table" rid="t1-body2">Table 1</xref>).</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gt01-en.jpg"/></table-wrap>
      <p>In this context, dopamine was replaced for dobutamine and antibiotic therapy was discontinued in the first 24 hours. A progressive decrease in CRP levels up to normal levels was later observed. Serial cardiac markers and electrocardiograms remained normal and the patient did not present rhythm or conduction disturbances.</p>
      <p>The radiographic images were reinterpreted as cardiogenic pulmonary edema, instead of the initial hypothesis of pneumonia. The fact that the radiographic changes resolved within the first few hours after mechanical ventilation was started, and that the adjustment in the treatment with amines resulted in improvement of the global cardiac function corroborate this hypothesis (<xref ref-type="fig" rid="en_16f1-body2">Figure 1</xref>).</p>
      <p>There was resolution of the circulatory shock in 72 hours, and the ventilatory parameters improved, thus permitting extubation on day 4. Echocardiography was repeated when the patient was no longer receiving amines, and showed improvement of the systolic function (ejection fraction of 52%) and regression of the global hypokinesia. The patient had a favorable cardiovascular outcome, and at discharge from the ICU she was alert and cooperative, hemodynamically stable and had no signs of heart failure.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>After other hypotheses had been ruled out, the acute cardiogenic shock was interpreted in the context of disulfiram poisoning. With persistently normal serum cardiac marker levels and echocardiograms, the diagnosis of acute myocardial infarction was excluded. No heart valve or other structural cardiac abnormalities consistent with dilated cardiomyopathy were found.</p>
      <p>In fact, progression to cardiogenic shock may be one of the severe complications of acute disulfiram poisoning, sometimes difficult to recognize in the initial approach to the patient. Besides being an uncommon complication, most of the patients are young and have no history of heart diseases.</p>
      <p>The hemodynamic instability may easily be interpreted within a context of sepsis or ARDS (acute respiratory distress syndrome) instead of circulatory failure resulting from drug poisoning, and this may lead to delayed assessment of the cardiac function.</p>
      <p>Manifestations of acute disulfiram poisoning result from the intensification of the acetaldehyde reaction when associated with alcohol, but mainly from the direct drug effects. There may be respiratory depression, neurological changes, acute myocardial infarction, arrhythmias, cardiac depression or cardiogenic shock, and even death<sup>3,4</sup>. When disulfiram was first introduced, very high doses used to be prescribed, sometimes of up to 3g/day, and this resulted in increased rates of severe or fatal reactions<sup>5</sup>. Doses were progressively adjusted, and these types of reaction are now uncommon and observed almost exclusively in cases of deliberate or accidental intake of clearly overtherapeutic doses, or in patients with previous cardiovascular disease. Nowadays, few cases are reported of cardiovascular collapse similar to that described here <sup>6,7</sup>.</p>
      <p>Since there is no specific antidote, aggressive support treatment has been the basis of therapy. Throughout the years, differences have been verified between the amines used as hemodynamic support, with norepinephrine proven to be more efficient than dopamine. This is thought to be due to the effects of diethyldithiocarbamate, one of disulfiram's metabolite, which attenuates the effect of the adrenergic response to hypotension by inhibiting dopamine beta-hydroxilase, the enzyme that converts dopamine into norepinephrine<sup>6,8</sup>. Norepinephrine depletion at the heart and vessels permits direct action of acetaldehyde in these tissues, thus producing the typical cardiovascular symptoms, including severe hypotension. This is also possibly the mechanism that leads to the global myocardial depression which later results in shock. In view of these data, norepinephrine or epinephrine seem to be appropriate options for the treatment of such cases<sup>9</sup>.</p>
      <p>The efficacy of dobutamine has never been sufficiently evaluated. In the present patient, dobutamine proved to be an efficient option.</p>
      <p>The role of the other drugs ingested in the development of the symptoms was questioned. After review of all its collateral effects, maprotiline (a tetracyclic antidepressant similar to tricyclic antidepressants) was confirmed as not being potentially able to lead to cardiogenic shock, unlike disulfiram.</p>
      <p>The major collateral effects of tricyclic antidepressants are cardiac conduction disturbances (prolonged QRS and QT-interval or atrioventricular block). They can also lead to postural hypotension (due to alpha-1-adrenergic receptor blockade), however in a mild degree that easily reverts with fluid therapy.</p>
      <p>Maprotiline is also less cardiotoxic than other antidepressants of the same group. Even in overdose situations, no severe hemodynamic effects such as cardiogenic shock are described, especially in patients without previous heart disease<sup>10</sup>.</p>
      <p>Thus, maprotiline was considered not to have contributed to the circulatory failure, and its effect, if any, would have been rapidly corrected by the aggressive therapeutic measures initially taken.</p>
      <p>Clonazepam (benzodiazepine) has few cardiovascular effects that mainly include palpitations, and does not have either a hypotensive or depressive cardiac action<sup>4</sup>.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Drug poisoning with disulfiram may have severe cardiovascular manifestations such as refractory cardiogenic shock and acute myocardial depression. These patients should be kept under strict medical surveillance and early cardiac function assessment should be performed. Invasive hemodynamic monitoring and ventilatory support in an intensive care environment may be necessary. Dopamine seems to be the least efficient amine in the management of disulfiram-induced shock.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Shockcardiog&#233;nico por disulfiram</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>La intoxicaci&#243;n medicamentosa por disulfiram es una situaci&#243;n rara, aunque puede presentarse con manifestaciones cardiovasculares graves y potencialmente fatales, como el shock cardiog&#233;nico. Este relato presenta el caso de una paciente con shock refractario, tras intoxicaci&#243;n voluntaria por disulfiram. La evaluaci&#243;n cl&#237;nica y bioqu&#237;mica, junto a la evaluaci&#243;n ecocardiogr&#225;fica y el monitoreo invasivo, confirmaron tratarse de un shock cardiog&#233;nico asociado a ese f&#225;rmaco. A lo largo del presente relato se discuten los mecanismos de acci&#243;n del disulfiram conocidos, as&#237; como se describen los principales efectos colaterales, espec&#237;ficamente los cardiovasculares. En este sentido, tambi&#233;n se alerta para la importancia de la sospecha diagn&#243;stica y del abordaje terap&#233;utico inmediato m&#225;s adecuado a este contexto.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Shock cardiog&#233;nico</kwd>
        <kwd>disulfiram</kwd>
        <kwd>efectos adversos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>INFORME DE CASO</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Shock cardiog&#233;nico por disulfiram</bold>
          </label>
          <p>
            <bold>Ana Jer&#243;nimo; Carla Meira; Augusta Amaro; Gl&#243;ria Cabral Campello; Cristina Granja</bold>
          </p>
        </fn>
      </p>
      <p>Servi&#231;o de Cuidados Intensivos, Hospital Pedro Hispano, Matosinhos - Portugal</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMO</bold>
      </p>
      <p>La intoxicaci&#243;n medicamentosa por disulfiram es una situaci&#243;n rara, aunque puede presentarse con manifestaciones cardiovasculares graves y potencialmente fatales, como el shock cardiog&#233;nico. Este relato presenta el caso de una paciente con shock refractario, tras intoxicaci&#243;n voluntaria por disulfiram. La evaluaci&#243;n cl&#237;nica y bioqu&#237;mica, junto a la evaluaci&#243;n ecocardiogr&#225;fica y el monitoreo invasivo, confirmaron tratarse de un shock cardiog&#233;nico asociado a ese f&#225;rmaco. A lo largo del presente relato se discuten los mecanismos de acci&#243;n del disulfiram conocidos, as&#237; como se describen los principales efectos colaterales, espec&#237;ficamente los cardiovasculares. En este sentido, tambi&#233;n se alerta para la importancia de la sospecha diagn&#243;stica y del abordaje terap&#233;utico inmediato m&#225;s adecuado a este contexto.</p>
      <p><bold>Palabras clave: </bold>Shock cardiog&#233;nico, disulfiram / envenenamiento, efectos adversos.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La intoxicaci&#243;n medicamentosa voluntaria se muestra un importante problema de salud en &#225;mbito mundial, ya que hay un n&#250;mero significativo de pacientes que se presentan en coma o con inestabilidad hemodin&#225;mica, lo que requiere ingreso a Unidades de Cuidados Intensivos (UCI). Antidepresivos, benzodiazepinas y organofosforados son los f&#225;rmacos que m&#225;s se utilizan, muchas veces asociados entre s&#237; y tambi&#233;n a bebidas alcoh&#243;licas<sup>1</sup>. Intoxicaciones voluntarias por disulfiram resultan raras, pero la gravedad de las complicaciones agudas exige que se sepa reconocer sus efectos t&#243;xicos.</p>
      <p>El disulfiram, utilizado para el tratamiento del alcoholismo, ejerce su acci&#243;n cuando hay ingesti&#243;n concomitante de alcohol. &#201;l inhibe de forma irreversible la enzima aldeh&#237;do deshidrogenasa, responsable de la metabolizaci&#243;n del etanol, con aumento de la concentraci&#243;n s&#233;rica del metabolito acetaldeh&#237;do, cuya toxicidad provoca el "s&#237;ndrome del acetaldeh&#237;do". Se trata de una reacci&#243;n t&#237;pica autolimitada, que tiene s&#237;ntomas como cefalea, <italic>flushing</italic>, v&#233;rtigo, n&#225;usea, visi&#243;n turbia, temblor y disnea<sup>2</sup>. No asociado a la ingesti&#243;n de alcohol, sus efectos se muestran escasos en las dosificaciones diarias habituales. Sin embargo, la intoxicaci&#243;n aguda en dosificaciones superiores a 500mg/d&#237;a puede tener como consecuencia efectos colaterales graves. La ingesti&#243;n de dosificaciones entre 10-30g/dia<sup>3</sup>, por su vez, puede ser letal.</p>
      <p>
        <bold>Relato de Caso</bold>
      </p>
      <p>Paciente del sexo femenino, 49 a&#241;os, con depresi&#243;n mayor y alcoholismo cr&#243;nico. Admitida en el servicio de urgencias cuatro horas tras la ingesti&#243;n voluntaria de 60 comprimidos de disulfiram (15g), 16 comprimidos de clonazepam (8mg) y 6 comprimidos de maprotilina (450mg), asociada al consumo de alcohol.</p>
      <p>Del examen cl&#237;nico, se destacaban somnolencia, taquipnea y mala perfusi&#243;n perif&#233;rica. Presi&#243;n arterial: 68-35mmHg; frecuencia cardiaca: 105 lpm. Ausculta pulmonar con estertores de burbuja difusos.</p>
      <p>De los resultados bioqu&#237;micos, resaltaba una cantidad de prote&#237;na C reactiva elevada (PCR): 31 mg/dl. La gasometr&#237;a revelaba hipoxemia grave (PaO2 66 mmHg, con FiO2 85%).</p>
      <p>Los marcadores de isquemia mioc&#225;rdica se mostraban negativos. El electrocardiograma revelaba taquicardia sinusal, sin alteraciones compatibles con isquemia aguda. La radiograf&#237;a de t&#243;rax presentaba opacidades alveolares bilaterales (<xref ref-type="fig" rid="es_16f1-body3">Fig 1</xref>).</p>
      <p content-type="asset">
        <fig id="es_16f1-body3">
          <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gf01-es.jpg"/></fig>
      </p>
      <p>Tras una adecuada resucitaci&#243;n con volumen, fue tratada con dopamina. Se hizo el rastreo microbiol&#243;gico y se inici&#243; antibioterapia de amplio espectro. A pesar de esas medidas, la paciente mantuvo el shock refractario y evolucion&#243; con agudizaci&#243;n de la dificultad respiratoria y desaturaci&#243;n progresiva, lo que exigi&#243; intubaci&#243;n orotraqueal e inicio de ventilaci&#243;n mec&#225;nica, motivos de su ingreso en la UCI.</p>
      <p>Se interpret&#243; inicialmente el caso como un cuadro de shock mixto -cardiog&#233;nico y s&#233;ptico. Se tom&#243; la sepsis como componente principal, con punto de partida en posible neumon&#237;a de aspiraci&#243;n debida a la postraci&#243;n. El componente cardiog&#233;nico ser&#237;a resultante de los efectos colaterales de los medicamentos ingeridos.</p>
      <p>Al persistir dudas respecto al grado de comprometimiento cardiaco, se realiz&#243; un ecocardiograma que mostr&#243; perjuicio moderado de la funci&#243;n sist&#243;lica del ventr&#237;culo izquierdo, con fracci&#243;n de eyecci&#243;n del 36% e hipocinesia global, sin otras alteraciones. Esos resultados motivaron monitoreo hemodin&#225;mico invasivo con cat&#233;ter de PICCO (<italic>Pulse Induced Continuous Cardiac Output</italic>), que confirm&#243; el perfil compatible con shock cardiog&#233;nico puro, con &#237;ndice cardiaco bajo y resistencias vasculares perif&#233;ricas elevadas (<xref ref-type="table" rid="t1-body3">Tabla 1</xref>).</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0e43-00016-gt01-es.jpg"/></table-wrap>
      <p>En este contexto, se sustituy&#243; la dopamina por dobutamina y se suspendi&#243; el antibi&#243;tico en las primeras 24h. Se verific&#243;, posteriormente, una reducci&#243;n progresiva de la PCR hasta la normalizaci&#243;n. Los marcadores cardiacos seriados y electrocardiograma permanecieron normales. La paciente no present&#243; perturbaciones de la conducci&#243;n o ritmo.</p>
      <p>Se reinterpretaron las im&#225;genes radiol&#243;gicas como edema pulmonar cardiog&#233;nico, en sustituci&#243;n de las hip&#243;tesis iniciales de neumon&#237;a. Corrobora esta hip&#243;tesis el hecho de que las alteraciones radiol&#243;gicas se hayan resuelto en las primeras horas tras el inicio de la ventilaci&#243;n mec&#225;nica y del ajuste de aminas, con mejor&#237;a de la funci&#243;n cardiaca global (<xref ref-type="fig" rid="es_16f1-body3">Fig 1</xref>).</p>
      <p>Se verific&#243; resoluci&#243;n del shock circulatorio al final de 72 horas y mejor&#237;a de los par&#225;metros ventilatorios, lo que permiti&#243; extubaci&#243;n al 4&#186; d&#237;a. Ya sin soporte de aminas, se repiti&#243; el ecocardiograma, que verific&#243; una mejor&#237;a de la funci&#243;n sist&#243;lica (fracci&#243;n de eyecci&#243;n 52%) y regresi&#243;n de la hipocinesia global. La paciente mantuvo evoluci&#243;n favorable del punto de vista cardiovascular, hasta recibir el alta de la UCI, despierta y colaborante, hemodin&#225;micamente estable y sin se&#241;ales de insuficiencia cardiaca.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Tras la exclusi&#243;n de otras hip&#243;tesis, se interpret&#243; el cuadro agudo de shock cardiog&#233;nico dentro del marco de la intoxicaci&#243;n medicamentosa por disulfiram. Con marcadores s&#233;ricos cardiacos y electrocardiograma persistentemente normales, se excluy&#243; el diagn&#243;stico de infarto agudo de miocardio. No hab&#237;a alteraciones valvulares o estructurales cardiacas compatibles con miocardiopat&#237;a dilatada.</p>
      <p>De hecho, la evoluci&#243;n para shock cardiog&#233;nico puede ser una de las complicaciones graves de la intoxicaci&#243;n aguda por disulfiram, aunque por veces es dif&#237;cil reconocerlo en el abordaje inicial del paciente. Adem&#225;s de tratarse de una complicaci&#243;n rara, los pacientes son en su mayor&#237;a j&#243;venes, sin antecedentes de patolog&#237;a cardiaca.</p>
      <p>Se puede interpretar f&#225;cilmente la inestabilidad hemodin&#225;mica, insertada en un cuadro de sepsis o SDRA (s&#237;ndrome de dificultad respiratoria aguda) en lugar de falencia circulatoria subsiguiente a la intoxicaci&#243;n medicamentosa. Esto retrasa la evaluaci&#243;n de la funci&#243;n cardiaca.</p>
      <p>Las manifestaciones de toxicidad aguda por disulfiram son consecuencias de la potenciaci&#243;n de la reacci&#243;n del acetaldeh&#237;do, cuando asociado al alcohol, pero, sobre todo, de los efectos directos del f&#225;rmaco. Pueden complicarse con depresi&#243;n respiratoria, alteraciones neurol&#243;gicas, infarto agudo de miocardio, arritmias, depresi&#243;n cardiaca o shock cardiog&#233;nico, y llevar a&#250;n a la muerte<sup>3,4</sup>. En los primeros a&#241;os de su utilizaci&#243;n, se prescrib&#237;a el disulfiram en dosificaciones muy elevadas -en algunos casos, hasta 3 g/d&#237;a-, lo que ha provocado una tasa incrementada de reacciones graves o fatales<sup>5</sup>. Las dosificaciones se han ajustado de modo que reacciones de este tipo ya resultan raras, observadas hoy, casi exclusivamente, en casos de ingesti&#243;n voluntaria o accidental con dosificaciones claramente supraterap&#233;uticas, o en pacientes con patolog&#237;a cardiovascular previa. En los d&#237;as actuales, pocos son los casos relatados de colapso cardiovascular con un cuadro semejante al descrito en esta paciente<sup>6,7</sup>.</p>
      <p>Visto que no existe ant&#237;doto espec&#237;fico, el tratamiento agresivo de soporte ha constituido la base terap&#233;utica. A lo largo de los a&#241;os, se ha constatado diferencias entre las aminas utilizadas como soporte hemodin&#225;mico. En este sentido, se verific&#243; que la noradrenalina resulta m&#225;s eficaz que la dopamina.</p>
      <p>Se cree que ello se deba a los efectos de uno de los metabolitos del disulfiram, el dietilditiocarbamato, que aten&#250;a el efecto de la respuesta adren&#233;rgica a la hipotensi&#243;n por medio de la inhibici&#243;n de la dopamina-beta-hidroxilasa, enzima que convierte la dopamina en noradrenalina<sup>6,8</sup>. La depleci&#243;n de noradrenalina en el &#225;mbito del coraz&#243;n y los vasos permite la acci&#243;n directa del acetaldeh&#237;do en esos tejidos, y produce los s&#237;ntomas t&#237;picos cardiovasculares, incluso hipotensi&#243;n grave. Es posible que sea tambi&#233;n el mecanismo que condiciona la depresi&#243;n mioc&#225;rdica global, la cual, posteriormente, lleva al shock. En funci&#243;n de esos datos, la noradrenalina o la adrenalina parecen ser opciones adecuadas para el tratamiento de esos casos<sup>9</sup>.</p>
      <p>Nunca se evalu&#243; suficientemente la eficacia de la dobutamina. En nuestra paciente, esta amina se mostr&#243; una alternativa eficaz.</p>
      <p>Se cuestion&#243;, sin embargo, el aporte de los restantes f&#225;rmacos ingeridos para el desarrollo del cuadro. Tras la revisi&#243;n de todos sus efectos colaterales, se confirm&#243; que la maprotilina (antidepresivo tetrac&#237;clico, semejante a los tric&#237;clicos), al rev&#233;s de lo que ocurre con el disulfiram, no presenta potencial para provocar situaciones de shock cardiog&#233;nico.</p>
      <p>Los principales efectos colaterales de los antidepresivos tric&#237;clicos son los disturbios de la conducci&#243;n cardiaca (ensanchamiento del QRS e intervalo QT o bloqueo auriculoventricular). Pueden a&#250;n provocar hipotensi&#243;n postural (por bloqueo de los receptores alfa-1 adren&#233;rgicos), aunque en nivel bajo, que se revierte f&#225;cilmente con fluidoterapia.</p>
      <p>La maprotilina se muestra, adem&#225;s de ello, menos cardiot&#243;xica que los dem&#225;s antidepresivos del mismo grupo. Aun en situaciones de sobredosificaci&#243;n, no se describen efectos hemodin&#225;micos graves como shock cardiog&#233;nico, sobre todo en pacientes sin cardiopat&#237;a previa<sup>10</sup>.</p>
      <p>De ese modo, se tomo en consideraci&#243;n que el aporte de la maprotilina para el cuadro de falencia circulatoria no fue determinante. Su efecto, si existe, ser&#237;a r&#225;pidamente corregido por las medidas terap&#233;uticas agresivas iniciales.</p>
      <p>El clonazepam (benzodiazepina) presenta escasos efectos cardiovasculares, que incluyen sobre todo palpitaciones. No presenta acci&#243;n hipotensora ni depresora cardiaca<sup>4</sup>.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La intoxicaci&#243;n medicamentosa por disulfiram puede presentar manifestaciones cardiovasculares graves, con shock cardiog&#233;nico refractario y depresi&#243;n mioc&#225;rdica aguda. Esos pacientes deben mantener una vigilancia cl&#237;nica estrecha y obtener una evaluaci&#243;n precoz de la funci&#243;n cardiaca. El monitoreo hemodin&#225;mico invasivo y el soporte ventilatorio en ambiente de Cuidados Intensivos pueden volverse necesarios. La dopamina parece ser la amina con menor eficacia en el abordaje del shock provocado por este f&#225;rmaco.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
